Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine vs NPH in Ethnic Minority T2DM
NCT00687453Phase 4Terminated
- Sponsor
- Charles Drew University of Medicine & Science
- Start
- Feb 2003
- Primary completion
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Charles Drew University of Medicine & Science. Primary endpoint: Hemoglobin A1c Change From Baseline at 6 months. Started Feb 2003; status: terminated.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00687453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687453.